Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)

Archives of Gynecology and Obstetrics

Volumn 286, Issue 2, 2012, Pages 437-442

  Engel, J B ^a   Schally, A V ^b,c   Buchholz, S ^a   Seitz, S ^a   Emons, G ^d   Ortmann, O ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

AEZS 108; Breast cancer; Doxorubicin; Endometrial cancer; EP 100; LHRH receptor positive cancers; Ovarian cancer; Targeted chemotherapy

Indexed keywords

CISPLATIN; DESLORELIN DOCETAXEL CONJUGATE; DOCETAXEL; DOXORUBICIN; EP 100; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARDIOTOXICITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESISTANCE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; HUMAN; IC 50; LEUKOPENIA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERSONALIZED MEDICINE; PROSTATE CANCER; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOGS; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INDIVIDUALIZED MEDICINE; MICE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; RATS;

EID: 84864422677     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2335-1     Document Type: Article

References (35)

1. Schally AV, Engel JB, Emons G et al (2011) Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv 8:11-25
2. Engel JB, Schally AV (2007) Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3:157-167
3. Schally AV, Comaru-Schally AM, Nagy A et al (2001) Hypothalamic hormones and cancer. Front Neuroendocrinol 22: 248-291
4. Schally AV, Nagy A (2004) Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15:300-310
5. Nagy A, Schally AV, Armatis P et al (1996) Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 93:7269-7273
6. Halmos G, Nagy A, Lamharzi N, Schally AV (1999) Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett 136(2):129-136
7. Westphalen S, Kotulla G, Kaiser F et al (2000) Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 17:1063-1069
8. Gunthert AR, Grundker C, Bongertz T et al (2004) Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 191:1164-1172
9. Schally AV, Nagy A (2003) New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 72:2305-2320
10. Emons G, Sindermann H, Engel J et al (2009) Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 90:15-18
11. Engel JB, Schally AV, Dietl J et al (2007) Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 4:652-658
12. Fekete M, Wittliff JL, Schally AV (1989) Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormonereleasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3:137-147
13. Bajo AM, Schally AV, Halmos G, Nagy A (2003) Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 9:3742-3748
14. Kahan Z, Nagy A, Schally AV et al (2000) Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Res Treat 59:255-262
15. Buchholz S, Seitz S, Schally AV et al (2009) Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. Int J Oncol 35:789-796
16. Foest C, Duwe F, Hellriegel M et al (2011) Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 25:1481-1487
17. Emons G, Ortmann O, Becker M et al (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53:5439-5446
18. Emons G, Pahwa GS, Brack C et al (1989) Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25:215-221
19. Srkalovic G, Schally AV, Wittliff JL et al (1998) Presence and characteristics of receptors for [D-Trip6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 12:489-498
20. Volker P, Grundker C, Schmidt O et al (2002) Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186:171-179
21. Miyazaki M, Nagy A, Schally AV et al (1997) Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 89:1803-1809
22. Arencibia JM, Schally AV, Krupa M et al (2001) Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. Int J Oncol 19:571-577
23. Srkalovic G, Wittliff JL, Schally AV (1990) Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormonereleasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50:1841-1846
24. Emons G, Schröder B, Ortmann O et al (1993) High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77:1458-1464
25. Grundker C, Volker P, Griesinger F et al (2002) Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 187: 528-537
26. Engel JB, Keller G, Schally AV et al (2005) Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertil Steril 83(Suppl 1):1125-1133
27. Buchholz S, Keller G, Schally AV et al (2006) Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. PNAS 103(27):10403-10407
28. Guenther E, Teifel M, Engel JB et al (2006) Targeting doxorubicin to LHRH-receptor positive tumors by the cytotoxic hybrid ZEN-008 (AN-152). EJC Suppl 4(12):159
29. Emons G, Kaufmann M, Gorchev G et al (2010) Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 119:457-461
30. Emons G, Tomov S, Harter P et al (2010) Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. J Clin Oncol (ASCO meeting abstracts 28(15) part 1:Abstract 5035)
31. Emons G, Sehouli J, Gorchev G et al (2010) Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. EJC Suppl 8(7):120
32. Leuschner C, Keener J, McCabe R, Patel N, Alila H (2009) Targeted oncolytic peptide for treatment of ovarian cancers. AACR meeting abstracts, Abstract 4666
33. (2009) Pharmacodynamics (PD) and pharmacokinetics (PK) study of EP-100 in advanced solid tumors. http://clinicaltrials. gov/ct2/show/NCT00949559
34. (2011) EP-100 plus paclitaxel versus paclitaxel alone in patients with ovarian cancer (ESP2011-002). http://clinicaltrials.gov/ct2/show/NCT01485848
35. Sundaram S, Durairaj C, Kadam R, Kompella UB (2009) Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther 8(6):1655-1665